New partnerships increase geographical footprint, supporting more access to patients and strengthening therapeutic capability

Dublin, Ireland – 10 November 2021 –   ICON plc, (NASDAQ: ICLR) a global provider of drug development and commercialisation services to pharmaceutical, biotechnology, medical device, and government organisations, today announced that its Accellacare Site Network has expanded in reach and capabilities through new partnerships with six research sites across four countries.
Agreements with Asclepes Research and Olympian Clinical Research in the United States, Curiositas ad Sanum and Intermed in Germany, Quironsalud in Spain, and KO-MED in Poland brings the Accellacare network to 112 active locations across eight countries and the entry to two new U.S. states – Florida and California. Through these new partnerships, Accellacare is also enhancing its already-strong capability in the central nervous system (CNS) and immune-inflammation therapeutic areas.

The expansion of the Accellacare Site Network increases access and engagement with investigative sites and its patients, supporting faster recruitment and reducing the overall time and cost associated with drug development for customers. Accellacare now has access to more than 9 million patients.
“Enrolling and engaging patients in clinical trials continues to be one of the biggest challenges within drug development,” said Alison Liddy, Senior Vice President, Site & Patient Solutions at ICON. “Our new Accellacare partnerships extend our ability to help customers enhance clinical trial feasibility and improve patient enrollment timelines in key therapeutic areas. We are committed to enhancing engagement with sites, patients and healthcare providers to reduce the overall time and costs of clinical development programmes for our customers.”

ICON launched Accellacare, a global clinical research network, in September 2020, providing patients easier and faster access to innovative treatments and offering customers the option to deploy decentralised trials. For customers, this approach leads to higher patient recruitment and retention rates, which generates operational efficiencies, accelerates study start-up timelines, and enhances study feasibility.

“As the clinical trial industry evolves past the COVID-19 pandemic, it is more important than ever to ensure we have a strong partner to continue to enable growth at our sites,” said Tim Welke, owner of Asclepes Research Centers. “Over the last several months, Accellacare has been a valuable member of our operation, allowing us to have more studies to offer our patients. Accellacare’s commitment and support to our site and each study aligns with our mission of improving patient care.”

About ICON plc and Accellacare

ICON is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON operates from 159 locations in 53 countries and has approximately 37,960 employees as of September 30, 2021. For more information, visit

Accellacare is a global clinical research network incorporating the Accellacare Site Network, In-Home Services and Site Resourcing. The Accellacare Site Network extends to 112 active research sites in eight countries with expertise in a wide range of therapeutic areas. It has relationships with more than 300 Principal Investigators, which connects the network to 9 million patients across its footprint. For more information, visit

About Asclepes Research Centers

Asclepes comprises specialized phase I-IV clinical pharmacology unit & research centers, offering unique expertise in psychiatry and central nervous system (CNS) research in the adult, geriatric, and pediatric population. Their network is also comprised of pediatric internal medicine, internal medicine, and oncology sites. They are proud to combine highest quality of research and state-of-the-art technology, while preserving staff integrity to ensure responsible and superior conduct of clinical research.

About Olympian Clinical Research

Olympian Clinical Research is a locally owned research group, founded in 2007 in Tampa, FL by Dr. Panos Vasiloudes, M.D., PhD. The group has experience conducting over 100 phase I through IV pharmacologic, nutraceutical, and device clinical trials in both adult and pediatric patients. They specialize in Dermatology, CNS, and Aesthetic clinical research, but have conducted many trials for a wide range of indications. Providing expert care while striving to generate the highest quality data are priorities, and they pride themselves on the good relationships they have built with Sponsors, CROs, and participants.  

About Curiositas ad Sanum

Curiositas ad Sanum has two study centers in Munich and Haag and has many years of experience in conducting clinical trials. Our investigators and study coordinators, have successfully conducted over 50 national and international studies (phases II – IV) in recent years, and we see more than 500 patients with neurological diseases annually.

About Intermed

Intermed, the Institute for Medical Research and Drug Safety, has been conducting studies to improve the effectiveness, tolerability and benefit of drugs since 1998. In addition to general medical indications, the focus is on the areas of CNS, pain, and pulmonology in collaboration with suitable specialists. Around 100 studies have been completed with leading pharmaceutical companies in which Intermed was designated “top recruiter” several times.

About Quironsalud

Quirónsalud is the leading hospital group in Spain. As part of the firm’s parent company, Fresenius-Helios, Quirónsalud also belongs to Europe’s largest family of hospitals. Outside of Spain, Quirónsalud also has operations in Latin America, particularly Colombia and Peru. The group has a total headcount of over 40,000 employees who work in more than 125 health centers, 54 of which are hospital facilities totaling 8,000 beds. Quirónsalud’s patients receive care that combines state-of-the-art technology and highly specialized, internationally renowned staff.

About KO-MED Clinical Centers

KO-MED Clinical Centers is a network of eleven clinical trial sites with a mission to provide patients the opportunity to regain health and contribute to the development of medicine. KO-MED has completed hundreds of clinical trials and repeatedly received the status of “top recruiter”, demonstrating the highest quality in clinical trials. KO-MED Clinical Centers take part in clinical trials phase I-IV specializes in oncology, cardiology, diabetology, allergology, rheumatology and more as well as in vaccines research.

Media Contacts:

Laurie Hurst
Sr Director, Public Relations & Communications, ICON plc
+1 919-274-3189 |

Weber Shandwick (PR adviser)
Lisa Henry (GMT time zone)
+447785 458203 |